Source: Contract Pharma

Sarepta Therapeutics: Genethon, Sarepta Choose Yposkesi as Mfg. Partner

CDMO's capacity to produce AAV materials at large-scale will support Genethon and Sarepta's project to take micro-dystrophin to clinical trials this year.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Sarepta Therapeutics's latest SEC filings

Annual Revenue

Based on data from Sarepta Therapeutics's latest SEC filings

Employees

Douglas S. Ingram's photo - President & CEO of Sarepta Therapeutics

President & CEO

Douglas S. Ingram

CEO Approval Rating

89/100

Sarepta develops and commercializes ribonucleic acid targeted therapeutics for the treatment of neuromuscular diseases.

S...
Read more